Abraxis Fails To Nix Naropin Suit Antitrust Claims

Law360, New York (July 31, 2008, 12:00 AM EDT) -- Abraxis BioScience Inc. was unable to toss antitrust cross-claims in its patent infringement case seeking to block a generic manufacturer from launching a copycat version of its injectable pain management drug Naropin.

Judge Joel A. Pisano of the U.S. District Court for the District of New Jersey on Thursday allowed Navinta LLC to hold on to its five counterclaims, but has granted Abraxis’ unopposed motion to bifurcate and stay the claims so that the patent issues can be addressed first.

Navinta’s claims are based on allegations...
To view the full article, register now.